← All trials
NCT05780463
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 11, 2021
- Primary completion
- Feb 23, 2022
- Completion date
- May 15, 2023
- First posted
- Mar 22, 2023
- Last posted
- Mar 24, 2023
- Enrollment
- 496
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Molecular Partners AGCollaborator
- AIDS Clinical Trials GroupCollaborator
- Medical Research CouncilCollaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- University of CopenhagenCollaborator
- University of CopenhagenOverall official - principal investigator
- University of MinnesotaCollaborator
- University of MinnesotaStudy chair
- Cardiothoracic Surgical Trials NetworkCollaborator
- University of New South WalesCollaborator
- Department of Veteran AffairsCollaborator
- Department of Veteran AffairsCollaborator
- International Network for Strategic Initiatives in Global HIV Trials (INSIGHT)Collaborator
- University of CopenhagenOfficial
- University of MinnesotaOfficial
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.